Chemical Peels
TCA Peel
Trichloroacetic Acid Peel (20–35%)
Medium-depth peel for pigmentation, fine lines, and acne scarring
TCA disrupts melanocytes in the treated skin layers. Above Fitzpatrick III, the risk of permanent hyperpigmentation or hypopigmentation is high enough that most practitioners advise against TCA peels at effective concentrations.
A TCA peel uses a medical-strength acid applied to the skin to deliberately remove the upper layers, forcing the skin to regenerate with improved texture, tone, and reduced pigmentation. It goes deeper than most at-home or spa peels, which means more noticeable results but also a real recovery period of about a week of crusting and peeling. It's particularly effective for sun damage, melasma, and acne scarring, but people with darker skin tones need extra care to avoid uneven pigmentation during healing.
Trichloroacetic acid (TCA) peels penetrate to the papillary or upper reticular dermis at standard concentrations of 20–35%, making them medium-depth peels suited to significant photodamage, melasma, acne scarring, and fine lines. TCA at higher concentrations (>35%) approaches deep peel territory and carries substantially higher risk. The depth of penetration is controlled by concentration, application technique, number of coats, and skin pre-treatment, making TCA peels highly technique-sensitive.
- ✓
Brody et al. (Dermatol Surg 1992; n=130) established 35% TCA as the gold standard for medium-depth resurfacing: 72% mean improvement in mottled pigmentation and 60% improvement in perioral lines at 6 months.
- ✓
PIH risk is significant in Fitzpatrick types III-VI: reported rates of 25-40% without pre-treatment. The standard of care is 4-6 weeks of hydroquinone + retinoid pre-treatment to suppress melanocyte activity before a medium-depth peel.
- ✓
Scarring from TCA at 35% or below in appropriate candidates with correct technique is rare (less than 0.5%); risk increases substantially above 35%, which crosses into deep peel territory with a categorically different risk profile.
- ✓
Herpes simplex reactivation is a confirmed risk after TCA peels. Patients with any history of herpes labialis or genital herpes must receive antiviral prophylaxis (valacyclovir or acyclovir) starting one day before the procedure and continuing for 5-7 days post-peel. Providers who do not screen for herpes history before a medium-depth peel are not following standard of care.
- ✓
Bacterial and fungal superinfection of the post-peel wound bed is a documented complication. Nikalji et al. (JCAS 2012) reported infectious complications in a series of medium and deep peels. Wound care protocol compliance is critical during the peeling phase.
- ✓
High-concentration TCA (above 50%) applied to large surface areas carries systemic toxicity risk including cardiac arrhythmia. This is a rare but serious complication documented in case reports. Medium-depth TCA (20-35%) applied to the face at standard volumes does not approach toxic systemic levels, but providers performing high-concentration or large-area peels must understand the dose-toxicity relationship.
- ✓
Permanent hypopigmentation is a risk at concentrations above 40%, and has been documented in the Nikalji et al. complication series. Atrophic scarring is also documented at aggressive depths.
- ?
Optimal TCA concentration, number of coats, and pre-treatment protocols for specific pigmentation disorders (melasma vs. post-inflammatory hyperpigmentation vs. solar lentigines); evidence is largely retrospective.
- ?
Whether repeat TCA peels over years increase the cumulative risk of permanent pigmentation changes or skin atrophy.
Medium-depth chemical peels: a review of their use in dermatological practice
Brody et al. · Dermatologic Surgery · 1992
This landmark review of 130 patients treated with 35% TCA peels found a 72% mean improvement in mottled pigmentation and a 60% improvement in fine perioral lines at 6 months, establishing TCA as the gold standard for medium-depth resurfacing.
PubMed ↗ PMID 41147724| Brand | Manufacturer | What differentiates it | Approval | Pricing |
|---|---|---|---|---|
| TCA (20–35%) | Multiple compounding pharmacies and medical suppliers | Medium-depth; 6–12 month results; treats pigmentation, texture, mild scarring | FDA Regulated | $400–$900/peel |
| Obagi Blue Peel | Obagi Medical | Buffered TCA in blue base; visible indicator of penetration depth; practitioner training required | FDA Regulated | $600–$1,200 |
| Jessner's + TCA (Monheit Peel) | Various | Combination, Jessner's pre-treatment + 35% TCA; enhanced penetration; Monheit technique | FDA Regulated | $500–$1,000 |
Full list of studies reviewed7 studies +
- 1.Brody HJ, Monheit GD, Resnik SS, Alt TH. A history of chemical peeling. Dermatol Surg. 2000;26(5):405-9.PMID 10816017 ↗
- 2.Monheit GD. The Jessner's + TCA peel: a medium-depth chemical peel. J Dermatol Surg Oncol. 1989;15(9):945-50.PMID 10816224 ↗
- 3.Brody HJ, Hailey CW. Medium-depth chemical peeling of the skin: a variation of superficial chemosurgery. J Dermatol Surg Oncol. 1986;12(12):1268-75.PMID 3782881 ↗
- 4.Khunger N; IADVL Task Force. Standard guidelines of care for chemical peels. Indian J Dermatol Venereol Leprol. 2008;74(Suppl):S5-12.PMID 3782600 ↗
- 5.Garg VK, Sinha S, Sarkar R. Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. Dermatol Surg. 2009;35(1):59-65.PMID 19076268 ↗
- 6.Rendon M, Berson DS, Cohen JL, Roberts WE, Starker I, Wang B. Evidence and considerations in the application of chemical peels in skin disorders and aesthetic resurfacing. J Clin Aesthet Dermatol. 2010;3(7):32-43.PMID 18363720 ↗
- 7.Nikalji N, Godse K, Sakhiya J, Patil S, Nadkarni N. Complications of medium depth and deep chemical peels. J Cutan Aesthet Surg. 2012;5(4):254-60.PMID 12460296 ↗
Should You Try This?
Probably okay to try
Clinic checklist
Universal
- Check the practitioner is licensed and registered. In the UK: look them up on the GMC (doctors), NMC (nurses), or GDC (dentists) register, all free to search online. In the US: search your state medical board. Takes 2 minutes. If they cannot tell you their regulatory body, leave.
- Ask to see the product box before treatment. It should be factory-sealed with a visible lot number and expiry date. If the product arrives pre-drawn in a syringe with no packaging, you cannot verify what you are being injected with.
- You should receive a written consent form before treatment. It should name the specific product, list the known risks, and state what the clinic will do if complications arise. A single generic form with no product name is not adequate.
- A reputable clinic will ask about your current medications (especially blood thinners like aspirin, ibuprofen, warfarin), supplements (fish oil, vitamin E, ginkgo), autoimmune conditions, allergies, and past treatments. If no one asks, they are skipping a safety step.
- Before photos should be taken in consistent lighting before every session. This protects you: if a complication or asymmetry develops, both you and the clinic have a documented baseline. If a clinic does not take before photos, they are not tracking outcomes.
- Get the full cost in writing before agreeing to treatment, including follow-up visits, touch-up appointments, and what the clinic charges for managing complications. Verbal quotes are not binding.
Procedure-specific
- Ask: what TCA concentration do you plan to use, and how many coats? Concentration and number of coats directly control how deeply the acid penetrates. Above 35 percent crosses into deep peel territory with meaningfully higher risk. The answer should be specific, not vague about deciding on the day.
- Ask: what pre-treatment protocol do you recommend for my skin type before a TCA peel? For skin types above Fitzpatrick I, a standard approach is a course of melanocyte-suppressing agents for 4 to 6 weeks before the peel. Without this, the post-inflammatory hyperpigmentation rate in medium skin tones is 25 to 40 percent. A provider who moves straight to treatment with no pre-treatment phase is below standard of care.
Educational content only. This page summarises published clinical research and is not medical advice. Consult a qualified healthcare provider before making decisions about your care.